News | June 09, 2014

Toshiba Re-enters U.S. Nuclear Imaging Market With New PET/CT System

Toshiba Re-enters U.S. Nuclear Imaging Market With New PET/CT System

June 9, 2014 — Toshiba America Medical Systems Inc. announced the release of its Celesteion system for positron emission tomography/computed tomography (PET/CT) imaging. The Celesteion is currently pending 510(k) clearance from the U.S. Food and Drug Administration (FDA).

The system combines high-performance PET and CT for all radiation and oncology imaging needs, including tumor detection, treatment evaluation and CT simulation. Features include:

  • A 90 cm CT and 88 cm PET bore, offering a feeling of openness for patients and more accurate CT and PET imaging;
  • Fast imaging for reduced exam times;
  • 450 ps time-of-flight resolution for PET;
  • 0.5-second rotation with 0.5 mm detectors producing 32 slices for CT;
  • 70 cm true CT and PET field-of-view and 85 cm CT extended field-of-view; and
  • Toshiba’s CT dose reduction technology, AIDR 3D, for safer CT imaging. The system is also compliant with MITA’s XR-29 Smart Dose standard.

“By listening to our customers and understanding their business, we know there is a need for a PET/CT system that puts patients first, and the Celesteion is that solution,” said Satrajit Misra, senior director, CT Business Unit, Toshiba. “Accuracy and efficiency are crucial under healthcare reform, and Celesteion is capable of producing high-quality images while improving workflow for providers.”

The Celesteion was first unveiled at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. It is Toshiba’s first nuclear imaging system for the American market in seven years and is an effort to capture larger a share of the SPECT (single-photon emission computed tomography) system replacement and first-generation PET/CT replacement market.

For more information: www.medical.toshiba.com

Related Content

 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

News | PET-CT | November 15, 2019
November 15, 2019 — According to an article published ahead-of-print in the...
Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can bee seen in this photo on either side of the patient bed. These can be rotated above the patient.

Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can be seen in this photo on either side of the patient bed. These can be rotated above the patient.

Feature | Nuclear Imaging | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — Philips Medical System is recalling the Forte Gamma Camera System due to the potential for the 660
 Phoenix’s fusion neutron generation technology.
News | Radiopharmaceuticals and Tracers | October 28, 2019
October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
A 3-D printed tungsten pre-clinical X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten pre-clinical X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | September 04, 2019 | By Steve Jeffery
In ...
A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one hold out who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one holdout who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

Feature | Nuclear Imaging | August 30, 2019 | Dave Fornell, Editor
In a surprising move, the National Institute for Radioelements (IRE) has applied for a new license to export highly e